{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:50:13Z","timestamp":1792461013262,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T00:00:00Z","timestamp":1687046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T00:00:00Z","timestamp":1687046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015993","name":"Kowa Company, Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12325-023-02534-w","type":"journal-article","created":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T12:01:45Z","timestamp":1687089705000},"page":"3559-3573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Crossover Randomized Study of Pharmacologic Effects of Ripasudil\u2013Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0356-7411","authenticated-orcid":false,"given":"Hidenobu","family":"Tanihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6683-0144","authenticated-orcid":false,"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6810-0583","authenticated-orcid":false,"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6940-1334","authenticated-orcid":false,"given":"Noriko","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3681-6402","authenticated-orcid":false,"given":"Hiroomi","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9130-0137","authenticated-orcid":false,"given":"Hideki","family":"Suganami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"K-232 Clinical Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Owada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Furuie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Hayashibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Mashimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Takat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,18]]},"reference":[{"key":"2534_CR1","volume":"12","author":"K Allison","year":"2020","unstructured":"Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus. 2020;12:e11686.","journal-title":"Cureus"},{"key":"2534_CR2","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221\u201334.","journal-title":"Lancet Glob Health"},{"key":"2534_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487\u201397.","journal-title":"Am J Ophthalmol"},{"key":"2534_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498\u2013505.","journal-title":"Am J Ophthalmol"},{"key":"2534_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"The AGIS Investigators","year":"2000","unstructured":"The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429\u201340.","journal-title":"Am J Ophthalmol"},{"key":"2534_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u201313 (discussion 829\u201330).","journal-title":"Arch Ophthalmol"},{"key":"2534_CR7","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268\u201379.","journal-title":"Arch Ophthalmol"},{"key":"2534_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48\u201356.","journal-title":"Arch Ophthalmol"},{"key":"2534_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ophtha.2006.07.060","volume":"114","author":"B Bengtsson","year":"2007","unstructured":"Bengtsson B, Leske MC, Hyman L, Heijl A, Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007;114:205\u20139.","journal-title":"Ophthalmology"},{"key":"2534_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","volume":"151","author":"T Krupin","year":"2011","unstructured":"Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S, Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151:671\u201381.","journal-title":"Am J Ophthalmol"},{"key":"2534_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ajo.2012.04.015","volume":"154","author":"CG De Moraes","year":"2012","unstructured":"De Moraes CG, Liebmann JM, Greenfield DS, et al. Risk factors for visual field progression in the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2012;154:702\u201311.","journal-title":"Am J Ophthalmol"},{"key":"2534_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003","volume":"101","author":"European Glaucoma Society","year":"2017","unstructured":"European Glaucoma Society. European Glaucoma Society terminology and guidelines for glaucoma, 4th edition\u2014chapter 3: treatment principles and options. Supported by the EGS Foundation. Br J Ophthalmol. 2017;101:130\u201395.","journal-title":"Br J Ophthalmol"},{"key":"2534_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10384-022-00970-9","volume":"67","author":"Y Kiuchi","year":"2023","unstructured":"Kiuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M, Glaucoma Guideline Preparation Committee, Japan Glaucoma Society. The Japan Glaucoma Society guidelines for glaucoma, 5th edition. Jpn J Ophthalmol. 2023;67:189\u2013254.","journal-title":"Jpn J Ophthalmol"},{"key":"2534_CR14","doi-asserted-by":"publisher","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, et al. Primary open-angle glaucoma Preferred Practice Pattern\u00ae. Ophthalmology. 2021;128:P71\u2013150.","journal-title":"Ophthalmology"},{"key":"2534_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10384-013-0284-2","volume":"58","author":"K Kashiwagi","year":"2014","unstructured":"Kashiwagi K, Furuya T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol. 2014;58:68\u201374.","journal-title":"Jpn J Ophthalmol"},{"key":"2534_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","volume":"12","author":"JC Tsai","year":"2003","unstructured":"Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393\u20138.","journal-title":"J Glaucoma"},{"key":"2534_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/IJG.0000000000001943","volume":"30","author":"YH Shu","year":"2021","unstructured":"Shu YH, Wu J, Luong T, et al. Topical medication adherence and visual field progression in open-angle glaucoma: analysis of a large US health care system. J Glaucoma. 2021;30:1047\u201355.","journal-title":"J Glaucoma"},{"key":"2534_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ajo.2022.11.017","volume":"248","author":"H Tanihara","year":"2023","unstructured":"Tanihara H, Yamamoto T, Aihara M, et al. Ripasudil\u2013brimonidine fixed-dose combination vs ripasudil or brimonidine: two phase 3 randomized clinical trials. Am J Ophthalmol. 2023;248:35\u201344.","journal-title":"Am J Ophthalmol"},{"key":"2534_CR19","doi-asserted-by":"publisher","first-page":"19640","DOI":"10.1038\/srep19640","volume":"6","author":"Y Kaneko","year":"2016","unstructured":"Kaneko Y, Ohta M, Inoue T, et al. Effects of K-115 (ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm\u2019s canal endothelial cells. Sci Rep. 2016;6:19640.","journal-title":"Sci Rep"},{"key":"2534_CR20","first-page":"101","volume":"7","author":"M Moshirfar","year":"2018","unstructured":"Moshirfar M, Parker L, Birdsong OC, et al. Use of Rho kinase inhibitors in ophthalmology: a review of the literature. Med Hypothesis Discov Innov Ophthalmol. 2018;7:101\u201311.","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"2534_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10384-018-0566-9","volume":"62","author":"M Honjo","year":"2018","unstructured":"Honjo M, Tanihara H. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma. Jpn J Ophthalmol. 2018;62:109\u201326.","journal-title":"Jpn J Ophthalmol"},{"key":"2534_CR22","doi-asserted-by":"publisher","first-page":"15255","DOI":"10.1038\/s41598-022-19271-9","volume":"12","author":"M Suzuki","year":"2022","unstructured":"Suzuki M, Suzuki Y, Komori R, et al. Aqueous column changes in the episcleral veins after the instillation of ripasudil versus latanoprost: a randomized, double-blind, crossover clinical trial. Sci Rep. 2022;12:15255.","journal-title":"Sci Rep"},{"key":"2534_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1749-6632.1995.tb32392.x","volume":"763","author":"J Burke","year":"1995","unstructured":"Burke J, Kharlamb A, Shan T, et al. Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys. A species difference. Ann N Y Acad Sci. 1995;763:78\u201395.","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 1","key":"2534_CR24","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S0039-6257(96)82027-3","volume":"41","author":"J Burke","year":"1996","unstructured":"Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41(Suppl 1):S9-18.","journal-title":"Surv Ophthalmol"},{"key":"2534_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136802","volume":"10","author":"H Nakagawa","year":"2015","unstructured":"Nakagawa H, Koizumi N, Okumura N, Suganami H, Kinoshita S. Morphological changes of human corneal endothelial cells after Rho-associated kinase inhibitor eye drop (ripasudil) administration: a prospective open-label clinical study. PLoS ONE. 2015;10: e0136802.","journal-title":"PLoS ONE"},{"key":"2534_CR26","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/40187","volume":"389","author":"M Uehata","year":"1997","unstructured":"Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990\u20134.","journal-title":"Nature"},{"key":"2534_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.exer.2005.07.015","volume":"82","author":"HA Reitsamer","year":"2006","unstructured":"Reitsamer HA, Posey M, Kiel JW. Effects of a topical \u03b12 adrenergic agonist on ciliary blood flow and aqueous production in rabbits. Exp Eye Res. 2006;82:405\u201315.","journal-title":"Exp Eye Res"},{"issue":"731\u20136","key":"2534_CR28","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(731\u20136): e2.","journal-title":"Am J Ophthalmol"},{"key":"2534_CR29","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1111\/aos.12599","volume":"93","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93:e254\u201360.","journal-title":"Acta Ophthalmol"},{"key":"2534_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","volume":"133","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133:755\u201361.","journal-title":"JAMA Ophthalmol"},{"key":"2534_CR31","unstructured":"Japanese Society of Ocular Allergology Committee on Guidelines. Japanese guideline for the management of allergic conjunctival diseases (3rd edition) [in Japanese]. https:\/\/www.nichigan.or.jp\/Portals\/0\/resources\/member\/guideline\/ACD3rd_chap2-2.pdf. Accessed 24 Jan 2023."},{"key":"2534_CR32","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2307\/2533558","volume":"53","author":"MG Kenward","year":"1997","unstructured":"Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53:983\u201397.","journal-title":"Biometrics"},{"key":"2534_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/eye.1997.43","volume":"11","author":"SF Nilsson","year":"1997","unstructured":"Nilsson SF. The uveoscleral outflow routes. Eye. 1997;11:149\u201354.","journal-title":"Eye"},{"key":"2534_CR34","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1080\/02713683.2016.1250276","volume":"42","author":"E Terao","year":"2017","unstructured":"Terao E, Nakakura S, Fujisawa Y, et al. Time course of conjunctival hyperemia induced by a Rho-kinase inhibitor anti-glaucoma eye drop: ripasudil 0.4%. Curr Eye Res. 2017;42:738\u201342.","journal-title":"Curr Eye Res"},{"key":"2534_CR35","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1038\/s41598-019-40255-9","volume":"9","author":"E Sakamoto","year":"2019","unstructured":"Sakamoto E, Ishida W, Sumi T, et al. Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% ripasudil ophthalmic solution clinical trial. Sci Rep. 2019;9:3755.","journal-title":"Sci Rep"},{"key":"2534_CR36","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","volume":"131","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131:1288\u201395.","journal-title":"JAMA Ophthalmol"},{"key":"2534_CR37","first-page":"453","volume":"122","author":"J Lee","year":"2018","unstructured":"Lee J, Komizo T, Ono T, et al. The effects of single combined administration of brimonidine and ripasudil on intraocular pressure, pupil diameter, and hyperemia in healthy subjects. J Jpn Ophthalmol Soc. 2018;122:453\u20139.","journal-title":"J Jpn Ophthalmol Soc"},{"key":"2534_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/bjophthalmol-2019-315776","volume":"105","author":"Y Maruyama","year":"2021","unstructured":"Maruyama Y, Ikeda Y, Mori K, et al. Morphological change and recovery of corneal endothelial cells after Rho-associated protein kinase inhibitor eye-drop (ripasudil 0.4%) instillation. Br J Ophthalmol. 2021;105:169\u201373.","journal-title":"Br J Ophthalmol"},{"key":"2534_CR39","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jcrs.2010.09.026","volume":"37","author":"G Shemesh","year":"2011","unstructured":"Shemesh G, Moisseiev E, Lazar M, Kesler A. Effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter. J Cataract Refract Surg. 2011;37:486\u20139.","journal-title":"J Cataract Refract Surg"},{"key":"2534_CR40","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1177\/0091270010385932","volume":"51","author":"E Besada","year":"2011","unstructured":"Besada E, Reed K, Najman P, Shechtman D, Hardigan P. Pupillometry study of brimonidine tartrate 0.2% and apraclonidine 0.5%. J Clin Pharmacol. 2011;51:1690\u20135.","journal-title":"J Clin Pharmacol"},{"key":"2534_CR41","first-page":"137","volume":"42","author":"M Honjo","year":"2001","unstructured":"Honjo M, Tanihara H, Inatani M, et al. Effects of Rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137\u201344.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2534_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3109\/02713683.2016.1148740","volume":"42","author":"T Satou","year":"2017","unstructured":"Satou T, Ishikawa H, Asakawa K, Goseki T, Shimizu K. Effects of ripasudil hydrochloride hydrate instillation on pupil dynamics. Curr Eye Res. 2017;42:54\u20137.","journal-title":"Curr Eye Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02534-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T04:16:06Z","timestamp":1688962566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02534-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,18]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2534"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02534-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,18]]},"assertion":[{"value":"16 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}